Literature DB >> 2501854

Antibody response in Crimean-Congo hemorrhagic fever.

A J Shepherd1, R Swanepoel, P A Leman.   

Abstract

IgG and IgM antibodies became demonstrable by indirect immunofluorescence on days 7 to 9 of illness in 35 survivors of Crimean-Congo hemorrhagic fever. Maximum titers of antibody were usually attained in the second to third week of illness. Titers of IgM declined gradually thereafter and were low or negative by the fourth month. In some patients titers of IgG increased markedly between 2 and 4 months after onset of illness and remained readily demonstrable by indirect immunofluorescence 3 years after infection. Endogenous antibody response was demonstrated in only two of 15 patients who died of infection. Techniques for demonstrating antibody were (in order of decreasing sensitivity) enzyme-linked immunosorbent assay, reversed passive hemagglutination-inhibition, indirect immunofluorescence, fluorescent-focus reduction, complement-fixation, and immunodiffusion. Most patients developed relatively low levels of neutralizing antibodies (range, 1:8 to 1:32 by fluorescent-focus reduction tests), but some developed titers of 1:256 to 1:512. Plasma intended for therapeutic use should be selected on the basis of its neutralizing ability.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2501854     DOI: 10.1093/clinids/11.supplement_4.s801

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  32 in total

1.  A virus-like particle system identifies the endonuclease domain of Crimean-Congo hemorrhagic fever virus.

Authors:  Stephanie Devignot; Eric Bergeron; Stuart Nichol; Ali Mirazimi; Friedemann Weber
Journal:  J Virol       Date:  2015-03-25       Impact factor: 5.103

2.  Crimean-Congo Hemorrhagic Fever Mouse Model Recapitulating Human Convalescence.

Authors:  David W Hawman; Kimberly Meade-White; Elaine Haddock; Rumi Habib; Dana Scott; Tina Thomas; Rebecca Rosenke; Heinz Feldmann
Journal:  J Virol       Date:  2019-08-28       Impact factor: 5.103

Review 3.  Diagnostic Testing for Crimean-Congo Hemorrhagic Fever.

Authors:  Vanessa N Raabe
Journal:  J Clin Microbiol       Date:  2020-03-25       Impact factor: 5.948

Review 4.  T Lymphocytes as Measurable Targets of Protection and Vaccination Against Viral Disorders.

Authors:  Anne Monette; Andrew J Mouland
Journal:  Int Rev Cell Mol Biol       Date:  2018-10-24       Impact factor: 6.813

5.  Investigation of tick-borne viruses as pathogens of humans in South Africa and evidence of Dugbe virus infection in a patient with prolonged thrombocytopenia.

Authors:  F J Burt; D C Spencer; P A Leman; B Patterson; R Swanepoel
Journal:  Epidemiol Infect       Date:  1996-06       Impact factor: 2.451

Review 6.  A chronological review of experimental infection studies of the role of wild animals and livestock in the maintenance and transmission of Crimean-Congo hemorrhagic fever virus.

Authors:  Jessica R Spengler; Agustín Estrada-Peña; Aura R Garrison; Connie Schmaljohn; Christina F Spiropoulou; Éric Bergeron; Dennis A Bente
Journal:  Antiviral Res       Date:  2016-10-03       Impact factor: 5.970

7.  Heterologous protection against Crimean-Congo hemorrhagic fever in mice after a single dose of replicon particle vaccine.

Authors:  Jessica R Spengler; Stephen R Welch; Florine E M Scholte; JoAnn D Coleman-McCray; Jessica R Harmon; Stuart T Nichol; Éric Bergeron; Christina F Spiropoulou
Journal:  Antiviral Res       Date:  2019-08-01       Impact factor: 5.970

8.  Evaluation of patients with Crimean-Congo hemorrhagic fever in Bolu, Turkey.

Authors:  A Duran; A Küçükbayrak; T Ocak; N I Hakyemez; T Taþ; M Karadađ; Z F Mengelođlu
Journal:  Afr Health Sci       Date:  2013-06       Impact factor: 0.927

9.  Pseudo-plaque reduction neutralization test (PPRNT) for the measurement of neutralizing antibodies to Crimean-Congo hemorrhagic fever virus.

Authors:  Nurettin Canakoglu; Engin Berber; Mustafa Ertek; Mustafa D Yoruk; Sukru Tonbak; Yusuf Bolat; Munir Aktas; Ahmet Kalkan; Aykut Ozdarendeli
Journal:  Virol J       Date:  2013-01-03       Impact factor: 4.099

10.  Follicular dendritic cell disruption as a novel mechanism of virus-induced immunosuppression.

Authors:  Eleonora Melzi; Marco Caporale; Mara Rocchi; Verónica Martín; Virginia Gamino; Andrea di Provvido; Giuseppe Marruchella; Gary Entrican; Noemí Sevilla; Massimo Palmarini
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-26       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.